#1 Clinical Trials Search in Europe

Cangrelor Tetrasodium

This article discusses a clinical trial comparing the effectiveness of two antiplatelet drugs, Cangrelor and Ticagrelor, in patients with ST-elevation myocardial infarction (STEMI). The study aims to evaluate the timing and method of drug administration to achieve optimal platelet inhibition and improve patient outcomes in acute coronary syndrome cases.

Table of Contents

What is Cangrelor Tetrasodium?

Cangrelor Tetrasodium, also known by its brand names Kengrexal or Kengreal, is a novel intravenous medication used in the treatment of certain heart conditions[1]. It belongs to a class of drugs called P2Y12 inhibitors, which are antiplatelet medications. These medications help prevent blood clots from forming in your arteries, which can be particularly important during and after certain heart procedures.

How Does Cangrelor Work?

Cangrelor works by inhibiting the P2Y12 receptor on platelets. Platelets are small blood cells that help your body form clots to stop bleeding. In some heart conditions, excessive platelet activity can lead to dangerous blood clots. By blocking the P2Y12 receptor, Cangrelor prevents platelets from sticking together, thus reducing the risk of clot formation[1].

Medical Conditions Treated with Cangrelor

Cangrelor is primarily used in the treatment of Acute Coronary Syndrome (ACS), particularly in cases of ST-elevation Myocardial Infarction (STEMI)[1]. Let’s break down these terms:

  • Acute Coronary Syndrome (ACS): This is an umbrella term for situations where the blood supply to the heart is suddenly blocked.
  • Myocardial Infarction: Commonly known as a heart attack, this occurs when blood flow to a part of the heart is blocked, causing damage to the heart muscle.
  • ST-elevation Myocardial Infarction (STEMI): This is a severe type of heart attack where a major artery supplying blood to the heart becomes completely blocked.

How is Cangrelor Administered?

Unlike many other antiplatelet medications that are taken orally, Cangrelor is administered intravenously (through a vein). In the clinical trial described, it’s given as a bolus (a large dose given quickly) of 30 μg/kg within 1 minute, followed by an infusion of 4 μg/kg/minute for two hours[1]. This method allows for rapid onset of action and precise control over the drug’s effects.

Cangrelor vs. Ticagrelor: A Comparison

Ticagrelor (brand names Brilique or Brilinta) is another antiplatelet medication used in similar conditions. However, there are some key differences[1]:

  • Administration: Ticagrelor is given orally, while Cangrelor is administered intravenously.
  • Onset of action: Cangrelor acts more quickly due to its intravenous administration.
  • Duration of effect: Cangrelor’s effects wear off quickly once the infusion is stopped, while Ticagrelor’s effects last for several days.
  • Flexibility: Cangrelor’s short-acting nature allows for more flexibility in managing patients who may need surgery or have a high bleeding risk.

Current Clinical Trial: Cangrelor vs. Ticagrelor in STEMI

A randomized controlled trial is currently comparing the effectiveness of Cangrelor and Ticagrelor in patients with STEMI[1]. The trial aims to determine:

  1. Whether Cangrelor administered in the hospital is as effective as Ticagrelor given in the ambulance in inhibiting platelet activity.
  2. If administering Cangrelor after coronary angiography (an X-ray examination of blood vessels in the heart) reduces inappropriate administration in patients who end up not having STEMI.

Potential Benefits of Cangrelor

Cangrelor offers several potential advantages in the treatment of acute coronary syndromes[1]:

  • Rapid onset: Its intravenous administration allows for immediate platelet inhibition.
  • Short half-life: The effects of Cangrelor wear off quickly once the infusion is stopped, which can be beneficial if a patient needs urgent surgery or has an increased bleeding risk.
  • Precision timing: It can be administered after coronary angiography, potentially reducing the risk of giving powerful antiplatelet drugs to patients who don’t need them.
  • Reversibility: Unlike some oral antiplatelet drugs, the effects of Cangrelor are quickly reversible, providing more flexibility in patient management.

As research continues, we’ll learn more about how Cangrelor compares to other antiplatelet medications and its optimal use in treating acute coronary syndromes.

Aspect Details
Study Type Randomized, controlled clinical trial
Condition ST-elevation Myocardial Infarction (STEMI)
Interventions 1. Oral Ticagrelor in ambulance
2. Intravenous Cangrelor in catheterization laboratory
Primary Outcome Platelet reactivity 10 minutes after PCI initiation
Secondary Outcomes 1. Platelet reactivity before and after PCI
2. Proportion of patients with inappropriate or harmful P2Y12 administration
Hypothesis Cangrelor administered in the catheterization laboratory is as effective as Ticagrelor administered in the ambulance for platelet inhibition in STEMI patients

FAQ

  • What is the main objective of this clinical trial? The main objective is to compare the effect of oral Ticagrelor administered in the ambulance versus intravenous Cangrelor administered in the catheterization laboratory on platelet inhibition in STEMI patients.
  • How are patients divided into groups in this study? Patients are randomly divided into two groups: one receiving oral Ticagrelor in the ambulance, and the other receiving intravenous Cangrelor in the hospital catheterization laboratory.
  • What is the primary outcome measure of the study? The primary outcome measure is platelet reactivity, measured in platelet reactivity units (PRU) by the VerifyNow® assay, 10 minutes after PCI (percutaneous coronary intervention) is initiated.
  • Why is the timing of antiplatelet drug administration important in STEMI cases? Early initiation of antiplatelet therapy is crucial to prevent further thrombus formation and facilitate primary PCI. However, there's a balance between achieving effective platelet inhibition and minimizing bleeding risks, especially for patients who may have a different final diagnosis.
  • What are the potential advantages of using Cangrelor in this setting? Cangrelor, being an intravenous drug with a short half-life, allows for immediate platelet inhibition that can be quickly reversed. This could potentially reduce the risk of administering powerful antithrombotic medicine to patients who may not have STEMI, while still providing effective platelet inhibition for those who do.

Ongoing Clinical Trials on Cangrelor Tetrasodium

  • Study of cangrelor with mechanical thrombectomy in patients with acute ischemic stroke selected by perfusion imaging

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Cangrelor and Bivalirudin for Patients with Heart Attack-Related Cardiogenic Shock or Cardiac Arrest on VA-ECMO Support

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Early vs. Delayed Ticagrelor with Cangrelor for Patients with STEMI Undergoing PCI

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • STEMI: ST-elevation Myocardial Infarction, a type of heart attack where a coronary artery is completely blocked, causing part of the heart muscle to die.
  • Platelet inhibition: The process of preventing blood platelets from clumping together and forming clots, which is important in treating and preventing heart attacks.
  • Percutaneous Coronary Intervention (PCI): A non-surgical procedure used to open blocked coronary arteries and restore blood flow to the heart muscle.
  • Ticagrelor: An oral antiplatelet medication that helps prevent blood clots in patients with acute coronary syndrome.
  • Cangrelor: An intravenous antiplatelet medication with a short half-life, used to prevent blood clots during PCI procedures.
  • Platelet reactivity: A measure of how easily platelets in the blood can form clots, used to assess the effectiveness of antiplatelet medications.
  • Thrombus: A blood clot that forms within a blood vessel, which can obstruct blood flow and cause serious health problems like heart attacks.
  • Antithrombotic therapy: Treatment that helps prevent the formation of blood clots, including antiplatelet and anticoagulant medications.
  • Catheterization laboratory: A specialized room in a hospital where minimally invasive tests and procedures of the heart and blood vessels are performed.
  • P2Y12 inhibitor: A class of antiplatelet drugs that work by blocking a specific receptor on platelets, helping to prevent blood clots.

References

  1. https://clinicaltrials.gov/study/NCT03182855